Further to this, the currently approved first line of treatment for NSCLC is immunotherapy alone for those patients with a high PD-L1 expression (≥50%) and a combination of chemotherapy + immunotherapy if the PD-L1 expression is below 50% [24,27,28,29], as long as no actionable molecular alterations can be targeted [30]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.